Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RC 28 E

Next Previous
X
Search
Drug Profile

RC 28 E

Alternative Names: RC-28-E; RC28-E injection

Latest Information Update: 06 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RemeGen; Yantai Rongchang Biological Engineering
  • Developer RemeGen
  • Class Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Fibroblast growth factor inhibitors; Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic macular oedema; Wet age-related macular degeneration
  • Phase II Diabetic retinopathy

Most Recent Events

  • 31 Jul 2023 RemeGen completes a phase II trial for Diabetic macular oedema (In adults, In the elderly) (Intravitreous) (NCT04782115)
  • 08 Jun 2023 Phase-III clinical trials in Diabetic macular oedema in China (Intravitreous) (NCT05885503)
  • 05 Jun 2023 Adverse events data from a phase I trial in Wet age-related macular degeneration released by RemeGen

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top